Peak Bio (NASDAQ:PKBO – Get Free Report) and ADMA Biologics (NASDAQ:ADMA – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.
Profitability
This table compares Peak Bio and ADMA Biologics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Peak Bio | N/A | N/A | -253.92% |
ADMA Biologics | 10.53% | 38.79% | 17.35% |
Valuation & Earnings
This table compares Peak Bio and ADMA Biologics”s revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Peak Bio | $370,000.00 | 11.25 | -$12.83 million | N/A | N/A |
ADMA Biologics | $330.24 million | 13.61 | -$28.24 million | ($0.02) | -969.25 |
Volatility & Risk
Peak Bio has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and price targets for Peak Bio and ADMA Biologics, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Peak Bio | 0 | 0 | 0 | 0 | N/A |
ADMA Biologics | 0 | 0 | 3 | 1 | 3.25 |
ADMA Biologics has a consensus target price of $15.50, suggesting a potential downside of 20.04%. Given ADMA Biologics’ higher possible upside, analysts plainly believe ADMA Biologics is more favorable than Peak Bio.
Insider & Institutional Ownership
75.7% of ADMA Biologics shares are held by institutional investors. 19.9% of Peak Bio shares are held by company insiders. Comparatively, 3.7% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
ADMA Biologics beats Peak Bio on 10 of the 12 factors compared between the two stocks.
About Peak Bio
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.
About ADMA Biologics
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Receive News & Ratings for Peak Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peak Bio and related companies with MarketBeat.com's FREE daily email newsletter.